prnewswire.com · 27 jul

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd.

prnewswire.com · 20 jul

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and wild-type overexpressing tumors. Signal activity including confirmed partial responses in heavily pretreated patients in multiple tumor types.

seekingalpha.com · 13 jul

Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk

Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim's pivotal epilepsy readout is probably the most important near-term catalyst that could validate their pipeline. They also have interesting, albeit early, positive findings with BHV-1300 and BHV-1400 for their degrader platform.

prnewswire.com · 9 jul

Biohaven Announces Scientific Leadership Transitions

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.

prnewswire.com · 30 jun

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026 Emerging opakalim focal epilepsy and idiopathic generalized epilepsy data presented at recent R&D Day reinforce evidence of target engagement, potential for efficacy, and differentiated tolerability profile In the ongoing focal epilepsy open-label extension (OLE) study, 54% of participants on opakalim 75 mg once-daily achieved a ≥50% reduction in seizure frequency compared to pre-randomization baseline, with a markedly lower incidence of nervous system adverse events compared to approved and investigational ASMs High double-blind completion rates of ~95%, and high rollover rates into the OLE of ~95%, reflect favorable patient experience with opakalim NEW HAVEN, Conn., June 30, 2026 /PRNewswire/ -- Biohaven Ltd.

benzinga.com · 29 jun

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an unfavorable risk-reward profile ahead of a key late-stage epilepsy trial.

benzinga.com · 29 jun

Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday.

prnewswire.com · 29 jun

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease

BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root of autoimmune disease. BHV-1300 targets the TSHR-IgG1 autoantibody that drives Graves' disease, not the thyroid gland itself.